Cassava Sciences Files 8-K on Financials

Ticker: FLNA · Form: 8-K · Filed: May 10, 2024 · CIK: 1069530

Cassava Sciences INC 8-K Filing Summary
FieldDetail
CompanyCassava Sciences INC (FLNA)
Form Type8-K
Filed DateMay 10, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-k, operations

Related Tickers: SAVA

TL;DR

SAVA dropped an 8-K on May 10th detailing financials - check it out.

AI Summary

On May 10, 2024, Cassava Sciences, Inc. filed an 8-K report detailing its financial results and operations. The company, incorporated in Delaware, is involved in the pharmaceutical preparations industry and is headquartered in Austin, Texas. This filing serves as a current report under the Securities Exchange Act of 1934.

Why It Matters

This filing provides investors with crucial updates on Cassava Sciences' financial condition and operational performance, which can influence investment decisions.

Risk Assessment

Risk Level: low — This is a standard 8-K filing reporting financial information and does not introduce new risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report current information about Cassava Sciences, Inc.'s results of operations and financial condition, as well as financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on May 10, 2024.

In which state is Cassava Sciences, Inc. incorporated?

Cassava Sciences, Inc. is incorporated in Delaware.

What is the business address of Cassava Sciences, Inc.?

The business address of Cassava Sciences, Inc. is 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, TX 78731.

What is the Standard Industrial Classification (SIC) code for Cassava Sciences, Inc.?

The Standard Industrial Classification (SIC) code for Cassava Sciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-05-10 16:07:16

Key Financial Figures

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On May 10, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. 99.1 Press Release dated May 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cassava Sciences, Inc. Date: May 10, 2024 By: /s/ Eric J. Schoen Eric J. Schoen Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing